Xeris Biopharma (XERS) Stock
Commercial biotech focused on room temperature hormone treatments. Here's the price, business snapshot, and what's worth knowing about Xeris Biopharma in June 2026.
Xeris BioPharma Holdings, Inc. (XERS) is a commercial-stage biotechnology company focused on developing ready-to-use hormone formulations and novel drug-delivery technologies. Its best-known offering is a room-temperature-stable glucagon product for severe hypoglycaemia, designed to simplify emergency treatment compared with traditional reconstitution therapies. With a market capitalisation of about $1.47bn, Xeris sits between early-stage biotechs and larger speciality pharmaceutical firms: it has commercial revenue but remains dependent on product uptake, pricing and reimbursement dynamics. Investors should watch sales growth, supply-chain execution, regulatory decisions and the company’s ability to expand indications or launch additional formulations. Typical biotech risks — clinical, regulatory, competition and financing — apply, and share prices can be volatile. This summary is educational and not personal advice; investors should assess their own suitability and consult a financial adviser before acting. Past performance is not indicative of future results.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Xeris Biopharma stock, expecting it to rise towards $11.14.
Financial Health
Xeris Biopharma is performing well with strong revenue and profit margins, suggesting solid financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring XERS
Ozempic Price Pressure | Pharma Investment Shift
A recent announcement of plans to slash prices for major weight-loss drugs has created turmoil for market leaders Novo Nordisk and Eli Lilly. This theme explores the investment opportunities that arise for competing pharmaceutical companies and developers of alternative treatments who may benefit from this market disruption.
Published: 21 October 2025
Explore BasketWeight-Loss Drug Shakeup: What's Next for Biotechs?
Following former President Trump's pledge to slash prices for popular weight-loss drugs, uncertainty has hit major pharmaceutical stocks. This theme identifies competitor firms and biotechs that could gain an edge as the pricing landscape for metabolic drugs shifts.
Published: 18 October 2025
Explore BasketInjectable Drug Revolution: What's Next Beyond Pills?
The UK's approval of GSK's long-acting HIV drug marks a pivotal shift from daily pills to less frequent injections. This theme focuses on the pharmaceutical innovators leading the charge in developing and commercializing long-acting therapeutic technologies.
Published: 17 October 2025
Explore BasketBeyond The Needle: The Oral GLP-1 Revolution
Eli Lilly's successful trial of its oral weight-loss drug, orforglipron, signals a major shift in the treatment landscape for obesity and diabetes. This theme focuses on the innovative pharmaceutical companies developing the next wave of convenient, non-injectable therapies poised to challenge the dominance of current market leaders.
Published: 28 August 2025
Explore BasketOral Obesity Treatments: Beyond The Needle
Following successful Phase 3 trials for its oral weight-loss drug, orforglipron, Eli Lilly is positioned to enter the lucrative obesity treatment market. This development creates a new investment theme focused on pharmaceutical companies developing patient-friendly, oral alternatives to injectable GLP-1 therapies.
Published: 27 August 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: 5 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Commercial traction watch
Sales growth and market penetration for its glucagon product will be key indicators, though revenues can fluctuate and depend on reimbursement.
Formulation innovation
Xeris’s ready-to-use formulations can simplify care and offer differentiation, but clinical and regulatory hurdles remain for new applications.
Market and competition
Competition from larger pharma and evolving treatment standards may affect pricing and uptake; market dynamics should be monitored closely.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
